Procédé de préparation d'un nouveau dérivé de la morpholine

1,160,468. Morpholine derivative. MAY & BAKER Ltd. 6 May, 1968 [8 May, 1967: 7 Nov., 1967]. Nos. 21240/67 and 50681/67. Heading C2C. Novel 2,6-dimethoxyphenyl 2-morpholinopropionate in the form of the racemate or an optically active isomer, and non-toxic acid addition salts thereof is prepared b...

Full description

Saved in:
Bibliographic Details
Main Authors EVAN LEE,GLYNN, FREDERICK BIGGS,DAVID, ROBERT WRAGG,WILLIAM, JOSEPH OWEN,ANTHONY, GEORGE BAMFORD,DAVID, WILLIAM PULSFORD,DEREK
Format Patent
LanguageFrench
Published 31.03.1970
Edition1
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:1,160,468. Morpholine derivative. MAY & BAKER Ltd. 6 May, 1968 [8 May, 1967: 7 Nov., 1967]. Nos. 21240/67 and 50681/67. Heading C2C. Novel 2,6-dimethoxyphenyl 2-morpholinopropionate in the form of the racemate or an optically active isomer, and non-toxic acid addition salts thereof is prepared by:- (a) reacting a compound of the Formula III: where X is the acid residue of a reactive ester with morpholine. or (b) reacting a compound of the Formula IV where Z is hydrogen or an alkali metal atom: with a compound of the Formula VII: where X 1 is a halogen atom; or (c) reacting 2,6-dimethoxyphenyl 2-aminopropionate with a compound of the formula X-(CH 2 ) 2 -O-(CH 2 ) 2 -X, where X is as defined above, in the presence of concentrated sulphuric acid. Enantiomorphic forms may be obtained by resolution of the racemate, or use of optically active starting materials. ( - )-α-Bromopropionyl chloride is obtained by treating the corresponding acid with thionyl chloride and phosphorus trichloride. (Œ) - 2,6 - Dimethoxyphenyl 2 - bromopropionate is obtained by adding (Œ)-α-bromopropionyl bromide in anhydrous benzene to a solution of 2,6-dimethoxyphenol and anhydrous pyridine in anhydrous benzene and then refluxing. (-) - 2,6 - Dimethoxyphenyl 2 - bromcpropionate is prepared similarly, but using ( - )- α-bromopropionyl chloride. Pharmaceutical compositions having local anaesthetic activity and containing 2,6-dimethoxyphenyl 2-morpholinopropionate and non- toxic acid addition salts thereof are administered parenterally in association with a pharmaceutical carrier. These compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing and solubilizing agents. They may be sterilized, e.g. by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the composition or by irradiation.
Bibliography:Application Number: CH19680006851